Neose Technologies, Inc., founded in 1989 and headquartered in Horsham, Pennsylvania, operates as a clinical-stage biopharmaceutical company. Their products, developed using GlycoPEGylation technology, aim to be competitive with leading protein drugs on the market. The company's pipeline includes GlycoPEG-GCSF for chemotherapy-induced neutropenia and GlycoPEGylated Factors VIIa, VIII, and IX for hemophilia, targeting markets with aggregate sales of approximately $8 billion in 2006.